Screening and Diagnosis Trends for Primary Aldosteronism: A Longitudinal Nationwide Study of 7.8 Million People

Clicks: 35
ID: 322698
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #22 of 122 articles by views in european journal of endocrinology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Primary aldosteronism (PA) is a common, treatable cause of hypertension for which screening is widely recommended but rarely performed in clinical practice. However, real-world screening and diagnosis patterns across the entire hypertensive population remain unknown. This study aimed to delineate the 22-year state of nationwide PA screening and diagnosis rates among all hypertensive population in Taiwan. METHODS: In this nationwide retrospective cohort study from 2001 to 2022, we identified all patients with hypertension using a national health insurance database. We calculated annual PA screening and diagnosis rates, with particular focus on high-risk subgroups, including patients with resistant hypertension, early-onset hypertension, hypokalemia, and other comorbidities warranting screening. RESULTS: Among 7.8 million patients with hypertension, a total of 4.4% received PA screening during the study period. The annual PA screening rate increased from 0.26% in 2001 to 0.75% in 2022 (p < 0.001) yet remained markedly low. In 2022, only 1.0% of patients with resistant hypertension, 3.2% with early-onset hypertension, and 3.6% with hypokalemia underwent screening. The diagnostic yield of PA showed a slight decrease over time, fluctuating between 8.0% and 6.7% (p = 0.006). CONCLUSION: Despite an increase in PA screening over the past two decades, absolute rates remain critically low, falling far short of guideline recommendations, even in high-risk groups. Our findings quantify a major implementation gap between evidence and clinical practice. As international guidelines are shifting towards broader and simpler screening protocols, there is an urgent need to improve the detection of this common and actionable condition.
Reference Key
openalex_W7171429643 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cheng‐Hsuan Tsai, Yu‐Cheng Chang, Zheng‐Wei Chen, Stéfanie Parisien‐La Salle, Jenifer M Brown, Anand Vaidya, Vin-Cent Wu, Yen‐Hung Lin
Are you one of these authors? Claim your profile
Journal european journal of endocrinology
Year 2026
DOI
10.1093/ejendo/lvag133
URL
https://doi.org/10.1093/ejendo/lvag133
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.